These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 22126026)

  • 1. Iron overload in nonalcoholic steatohepatitis.
    Fujita N; Takei Y
    Adv Clin Chem; 2011; 55():105-32. PubMed ID: 22126026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hepatic iron in non-alcoholic steatohepatitis.
    Sumida Y; Yoshikawa T; Okanoue T
    Hepatol Res; 2009 Mar; 39(3):213-22. PubMed ID: 19261002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis.
    Fujita N; Miyachi H; Tanaka H; Takeo M; Nakagawa N; Kobayashi Y; Iwasa M; Watanabe S; Takei Y
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):424-32. PubMed ID: 19190144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil.
    Torres DM; Harrison SA
    Semin Liver Dis; 2012 Feb; 32(1):30-8. PubMed ID: 22418886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From fatty liver to fibrosis: a tale of "second hit".
    Basaranoglu M; Basaranoglu G; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1158-65. PubMed ID: 23483818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathogenesis and clinical consequences of iron overload in liver cirrhosis.
    Sikorska K; Bernat A; Wroblewska A
    Hepatobiliary Pancreat Dis Int; 2016 Oct; 15(5):461-479. PubMed ID: 27733315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis.
    Chitturi S; George J
    Curr Gastroenterol Rep; 2003 Feb; 5(1):18-25. PubMed ID: 12530944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of iron overload in the progression of nonalcoholic steatohepatitis (NASH)].
    Atarashi M; Izawa T; Kuwamura M; Yamate J
    Nihon Yakurigaku Zasshi; 2019; 154(2):61-65. PubMed ID: 31406044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mice lacking liver-specific β-catenin develop steatohepatitis and fibrosis after iron overload.
    Preziosi ME; Singh S; Valore EV; Jung G; Popovic B; Poddar M; Nagarajan S; Ganz T; Monga SP
    J Hepatol; 2017 Aug; 67(2):360-369. PubMed ID: 28341391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary iron overload in the African and hepatocellular carcinoma.
    Kew MC; Asare GA
    Liver Int; 2007 Aug; 27(6):735-41. PubMed ID: 17617115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis.
    Gao H; Jin Z; Bandyopadhyay G; Wang G; Zhang D; Rocha KCE; Liu X; Zhao H; Kisseleva T; Brenner DA; Karin M; Ying W
    Cell Metab; 2022 Aug; 34(8):1201-1213.e5. PubMed ID: 35921818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of disease progression in nonalcoholic fatty liver disease.
    Jou J; Choi SS; Diehl AM
    Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis.
    Sorrentino P; D'Angelo S; Ferbo U; Micheli P; Bracigliano A; Vecchione R
    J Hepatol; 2009 Feb; 50(2):351-7. PubMed ID: 19070395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational approaches: from fatty liver to non-alcoholic steatohepatitis.
    Rosso N; Chavez-Tapia NC; Tiribelli C; Bellentani S
    World J Gastroenterol; 2014 Jul; 20(27):9038-49. PubMed ID: 25083077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.